A Phase I/II Study of the EGF Vaccine CIMAvax in Combination with the Anti-PD1 Nivolumab in Patients with Previously Treated Advanced NSCLC
This phase I/II trial studies the best dose and side effects of CIMAvax vaccine and nivolumab and to see how well they work in treating patients with stage III-IV non-small cell lung cancer. Vaccine therapy, such as CIMAvax vaccine may help slow down and stop tumor growth. Monoclonal antibodies, such as nivolumab, may block a protein needed by tumor cells to grow and spread. Giving CIMAvax vaccine together with nivolumab may work better in treating patients with stage IIIB-IV non-small cell lung cancer.